MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma.

[1]  G. Samimi,et al.  Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  H. Lage,et al.  RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. , 2004, Gynecologic oncology.

[3]  Y. Sugiyama,et al.  Characterization of the Cellular Localization, Expression Level, and Function of SNP Variants of MRP2/ABCC2 , 2004, Pharmaceutical Research.

[4]  S. Howell,et al.  Short-termcis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells , 2004, Cancer Chemotherapy and Pharmacology.

[5]  M. Gottesman,et al.  Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. , 2003, Cancer research.

[6]  D. Schadendorf,et al.  Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. , 2003, The Journal of investigative dermatology.

[7]  C. Bokemeyer,et al.  Molecular determinants of treatment response in human germ cell tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  J. Kigawa,et al.  Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. , 2002, Gynecologic oncology.

[9]  G. Sandusky,et al.  Expression of multidrug resistance‐associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays , 2002, Histopathology.

[10]  A. deFazio,et al.  Scientists and clinicians test their metal-back to the future with platinum compounds. , 2002, The Lancet. Oncology.

[11]  L. Einhorn.  Curing metastatic testicular cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[13]  M. Gottesman,et al.  Overview: ABC Transporters and Human Disease , 2001, Journal of bioenergetics and biomembranes.

[14]  J. Doroshow,et al.  Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. , 2001, Blood.

[15]  D. Keppler,et al.  Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma , 2001, International journal of cancer.

[16]  D. Keppler,et al.  Up‐regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver , 2001 .

[17]  M. Kuwano,et al.  Identification of the Apical Membrane-targeting Signal of the Multidrug Resistance-associated Protein 2 (MRP2/cMOAT)* , 2001, The Journal of Biological Chemistry.

[18]  M. Kool,et al.  Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. , 2000, Cancer research.

[19]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[20]  J. Verweij,et al.  Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M. Kool,et al.  Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  T. Uchiumi,et al.  Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2) , 1999, FEBS letters.

[23]  D. Keppler,et al.  Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. , 1999, Journal of the American Society of Nephrology : JASN.

[24]  D. Keppler,et al.  Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. , 1999, Molecular pharmacology.

[25]  R. Evers,et al.  Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. , 1999, The Biochemical journal.

[26]  M. Kool,et al.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.

[27]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[28]  K. Kohno,et al.  A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. , 1996, Cancer research.

[29]  B. Goodwin,et al.  Interferon γ down‐regulates cytochrome P450 3A genes in primary cultures of well‐differentiated rat hepatocytes , 1996, Hepatology.

[30]  P. Bosma,et al.  Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene , 1996, Science.

[31]  S. Cannistra.  Paclitaxel in ovarian cancer: how can we make it better? , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[33]  L. Kèlland,et al.  Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. , 1992, British Journal of Cancer.

[34]  G. Laurie,et al.  Basement membrane complexes with biological activity. , 1986, Biochemistry.

[35]  Ozols Rf.  Pharmacologic reversal of drug resistance in ovarian cancer. , 1985 .

[36]  J. Riordan,et al.  Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. , 1983, Cancer research.